The concept of combining a specific small molecule CBP/β-catenin antagonist with immunotherapy to reverse Wnt/β-catenin-mediated cancer immune evasion has been previously explored preclinically in NAFLD-associated liver cancer (60) and colorectal cancer to liver metastasis (28). Here, CREBBP is linked to metabolic dysfunction-associated steatotic liver disease.